<DOC>
	<DOC>NCT01003028</DOC>
	<brief_summary>This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.</brief_summary>
	<brief_title>Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled Infusion</brief_title>
	<detailed_description />
	<mesh_term>Remifentanil</mesh_term>
	<criteria>1870 year old ASA class 13 scheduled for elective surgery history of neurologic or mental disorder uncontrolled pulmonary or cardiovascular disease history of adverse reactions to opioids history of drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Total intravenous anesthesia</keyword>
	<keyword>Maximum plasma concentration of remifentanil</keyword>
</DOC>